

128 DAUS
IN THE UNITED STATES PATENT & TRADEMARK OFFICE 7.14.95

Applicant: Kenneth W. Batchelor, et al.
Filed: March 16, 1995
Title: ANDROSTENONE DERIVATIVE

Serial No: 08/405,120
Art Unit:
Examiner:

INFORMATION DISCLOSURE STATEMENT

COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, DC 20231

Dear Sir:


In accordance with 37 CFR § 1.56, applicant wishes to call to the attention of the Examiner the enclosed references. The PTO-1449 does not constitute an admission that any of the listed references, which are cited only as constituting the closest art of which applicant is aware, is relevant or material to the claims.

The Commissioner is authorized to charge any fees due with submission of this Information Disclosure Statement to Deposit Account 07-1392. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: 06/26/95

Glaxo Inc.
Five Moore Drive
Research Triangle Park, NC 27709


Charles E. Dadswell
Registration No. 35,851
Attorney for Applicants
Telephone: (919) 990-6983
Facsimile: (919) 248-7988

Certificate of Mailing (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: The Commissioner of Patent and Trademarks, Washington, D.C. 20231
on 7 JULY 1995

7 JULY 1995

Date

Rosalie M. Germano